Terese Hammond, MD
Pulmonary Disease · Santa Monica, CANPI 1407831829
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,675 of the $9,953 with a category attached, or 67.1%. 6 manufacturers reported payments, led by Abiomed at 37.5% of the total. Reporting peaked in 2022 at $5,825 and has fallen 98.4% since, to $95 in 2025.
Across 19 payments — averaging $523.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$4K
- Pfizer$4K
- Regeneron$2K
- Ceribell, Inc.$255
- Johnson & Johnson$133
- Biomerieux Inc$8
Across 133 payments — averaging $18,782 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.9M
- Gilead$506K
- Novartis$52K
- Hoffmann-la Roche Limited$31K
What the payments were for
- Consulting fees$2,15022%
- Speaking & faculty fees$6,67567%
- Travel & lodging$7327%
- Food & beverage$3964%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 7 | $3,732 |
| Pfizer | 4 | $3,675 |
| Regeneron | 2 | $2,150 |
| Ceribell, Inc. | 2 | $255 |
| Johnson & Johnson | 3 | $133 |
| Biomerieux Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$3,563
How this compares
$9,953 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $33,910 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $8,561 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,318 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $2,446 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $933 |
| Montelukast Sodium | 20 | $281 |
| Azithromycin | 22 | $254 |
| Prednisone | 38 | $232 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Santa Monica
- Reza RonaghiSanta Monica$390K
- Tao HeSanta Monica$214K
- Rodrigo Garcia TomeSanta Monica$92K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.